Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
PEGylated liposomal topotecan has enhanced safety and efficacy in mice
December 29th, 2005
The use of PEGylated liposomes for delivery improves the safety and efficacy of topotecan treatment in murine cancer models. According to recent research from China, "in an attempt to increase the accumulation of topotecan in tumors and improve its anticancer activity, PEGylated liposome (H-PEG) containing topotecan was prepared." "The in vitro cytotoxicity, in vivo biodistribution pattern and antitumor effect of H-PEG were studied systemically," explained Y.L. Lao and coauthors at the Beijing Union Medical College Hospital. They found that, "compared with free topotecan or conventional liposome (H-Lip), H-PEG improved the cytotoxic effect of...
Source: Women's Health Weekly (2005-12-29)
|
